#ESMO26 | LBA6
🚨 SAFFRON (Phase 3)
Osimertinib + savolitinib vs platinum–pemetrexed in EGFRm/MET-high NSCLC after 1L/2L osimertinib (n=338).
🧬🔬 严格的 MET 筛选：
IHC 3+ 在 ≥90% 的肿瘤细胞中和/或 MET 基因拷贝数 ≥10（FISH 法）。
✅ mPFS：7.6 对 5.4 个月（HR 0.55；P<0.001）
✅ mOS：17.8 对 12.9 个月（HR 0.68；P=0.010）
✅ mDoR：9.7 对 5.7 个月
💡 PFS 获益在 MET-OE 和 MET-AMP 亚组中一致。
⚠️ 安全性：
• 3 级及以上 TRAE：40% 对 52%
• 导致停药的 TEAE：14% 对 8%
首个全球 III 期研究在 MET 筛选的 EGFRm NSCLC 奥希替尼后显示显著 OS 获益，支持一种新的靶向治疗选择。
#LCSM
315 浏览 · 8 赞 · 1 转发 · 0 回复
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgINTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgPerioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgDarolutamide with androgen deprivation therapy (ADT) and definitive or salvage locoregional radiation therapy (RT) for localised, very high-risk prostate cancer: Interim analysis of an international, placebo-controlled, randomised phase 3 t
https://esmocongress.esmo.orgSustained survival with extended follow-up of tarlatamab plus anti-PD-L1 as first-line maintenance (1LM) after chemoimmunotherapy for extensive-stage small cell lung cancer (ES-SCLC): DeLLphi-303 phase 1b study
https://esmocongress.esmo.orgKrascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer
https://esmocongress.esmo.org1/4 🔥 #ESMO26 Lung Cancer Presidential Highlights 🇪🇸 Madrid | October 24–25, 2026 Three major Phase 3 lung cancer LBAs, each with potential to reshape treatment paradigms: 🎙️ LBA3 | DeLLphi-305 🎙️ LBA5 | KRASCENDO 1 🎙️ LBA6 | SAFFRON Three Phase 3 readouts to watch closely at #ESMO26 👀 @myESMO @OncoAlert @Larvol在 X 查看被引用的帖子
来源：Masahiro TORASAWA, MD. PhD. · x.com